Fig. 2. Hepatocyte-specific deletion of Acsl4 does not enhance tumor formation in STZ-HFD model.
A Scheme of the STZ-HFD mouse model for HCC. Serum levels of aspartate transaminase (AST) and alanine transaminase (ALT) (B), as well as liver-to-body weight ratios (C) were measured in untreated, as well as Acsl4f/f and Acsl4∆hepa mice after 12 and 20 weeks of treatment. D Representative liver pictures from untreated and STZ-HFD-treated mice. Scale bars: 1 cm. E H&E staining of liver sections from untreated and STZ-HFD-treated mice. Scale bars: 100 µm.Tumor incidence (F), the total number of tumors (G), the number of tumors smaller than 0.5 cm and the number of tumors larger than or equal to 0.5 cm (H), the median tumor volume and the largest tumor volume per mouse (I), and the total tumor burden (J) were determined in Acsl4f/f and Acsl4∆hepa mice after 12 and 20 weeks of treatment. Data are expressed as mean ± SEM from 10 to 12 mice per group. *p < 0.05; unpaired t test comparing Acsl4∆hepa to Acsl4f/f mice for each time point.